MaryClareSpellmanMD

Dermatology • San Francisco, CA

Physician

Join to view full profile

Dr. Spellman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Spellman's full profile

Already have an account?

Office
28 Miguel St
San Francisco, CA 94131
Phone+1 415-652-7962

Fax+1 415-520-5533

Education & Training

Medical College of Wisconsin Affiliated HospitalsResidency, Dermatology, 1989 - 1992
McGaw Medical Center of Northwestern UniversityInternship, Internal Medicine, 1988 - 1989
Medical College of WisconsinClass of 1988

Certifications & Licensure

CA State Medical License 1992 - 2025
WI State Medical License 1989 - 1997
American Board of Dermatology Dermatology

Clinical Trials

Intratumoral PH-762 for Cutaneous Carcinoma Start of enrollment: 2023 Nov 07
Recruiting
Phase 1
Roles: Contact

Publications & Presentations

PubMed

337 citations
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children...
Amy S. Paller, Wynnis L. Tom, Mark Lebwohl, Robin L. Blumenthal, Mark Boguniewicz
Journal of the American Academy of Dermatology. 2016-09-01
54 citations
The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-Type Psoriasis of Nonscalp Regions:
Alice B. Gottlieb, Rosanne Odom Ford, Mary C. Spellman
Journal of Cutaneous Medicine and Surgery. 2003-04-22
159 citations
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
Alice B. Gottlieb, James G. Krueger, Ross Bright, Mark Ling, Mark Lebwohl
Journal of the American Academy of Dermatology. 2000-03-01

Lectures

Late-breaking Research: Clinical Trials
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019

Press Mentions

Phio Pharmaceuticals Receives FDA IND Clearance for PH-762 TrialMay 17th, 2023
Castle Creek Pharmaceuticals Appoints Mary Spellman, M.D., as Chief Medical Officer and Senior Vice President of Research & DevelopmentJune 3rd, 2019
Spellman Named CMO of Convoy TherapeuticsJuly 18th, 2019

Professional Memberships

American Academy of Dermatology - AAD
Member